Kerey Pharm
Xinshao, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Chinese API manufacturer using biosynthetic technology to produce pharmaceutical intermediates and active ingredients from plant sterols.
OphthalmologyUrologyDermatology
Technology Platform
Biosynthetic technology utilizing plant sterols as starting materials, with bio-fermentation processes to produce pharmaceutical intermediates followed by chemical conversion to final APIs.
Opportunities
Growing global demand for cost-effective APIs and intermediates, particularly for established compounds like finasteride and dutasteride, plus potential expansion into ophthalmology and medical device segments.
Risk Factors
Intense competition in generic API manufacturing, price pressure, regulatory compliance challenges, and potential disconnect between stated ophthalmology focus and actual chemical synthesis business.
Competitive Landscape
Competes with other Chinese API manufacturers like Zhejiang Xianju Pharmaceutical and Dr. Reddy's in the generic finasteride/dutasteride space, differentiating through biosynthetic technology and FDA-certified manufacturing capabilities.